Nautilus Q1 net loss $18.7M vs $15.0M YoY; cash $247.7M

Nautilus Biotechnology, Inc.

2024-Q1 EPS reported -$0.15

Net loss of $18.7M widened from $15.0M in Q1 2023; no revenue reported.
Operating expenses $21.6M, up 20% YoY on higher headcount for platform development.
Cash, equivalents and investments $247.7M as of March 31, 2024.
CEO cites progress on consumables, assay, instrument and software scale/reproducibility.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Nautilus Biotechnology, Inc. reported the first quarter ended March 31, 2024 results: net income $18.7 million.

Period: the first quarter ended March 31, 2024
Net income: $18.7 million
Result: reported results

Exact text from the filing

Net loss was $18.7 million for the first quarter of 2024

View on SEC.gov

1447 earnings releases filed in the last 30 days. Browse all earnings releases →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-24-000038

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.